Jeil Pharmaceutical Files 2025 Corporate Governance Report: Improvements in Electronic Voting but No Dividends and Persistent Non-Compliance
FY2025 consolidated revenue fell 19.5% to 567.2B KRW, but operating profit turned positive to 20.7B KRW (vs -18.9B in 2024) and net profit was 32.0B KRW (vs -30.1B). No cash dividends were paid for 2024 and 2025 due to insufficient retained earnings.
Failed to provide AGM notice 4 weeks in advance (only 15 days), a key governance indicator non-compliance. Reason cited is scheduling conflicts with affiliates; internal improvements are underway.
Introduced electronic voting starting from the 9th AGM to enhance shareholder voting convenience, but has not adopted mail-in voting. Continues to avoid peak AGM dates to encourage participation.
Board consists of 5 inside and 3 outside directors (all male), with all outside directors serving on the audit committee. CEO also serves as board chair; no separation of roles. Lack of gender diversity.
Established a CEO succession policy for the first time, completed internal accounting management system and compliance certification (ISO 37001/37301), strengthening internal controls.
Audit committee comprises 3 independent directors, holds quarterly meetings with external auditors without management presence. External auditor is Ichon Accounting Firm; no non-audit services provided.
Dividend policy is not codified; predictability is lacking. Articles were amended at the 9th AGM to improve dividend procedures, but no concrete dividend plan has been set.
Related party transactions: advisory fees of 6.6B KRW and loan of 5B KRW to parent Jeil Pharma Holdings; 57.3B KRW in sales and purchases with subsidiary Onconic Therapeutics. Collateral of 40B KRW in land and buildings provided by Jeil Pharma Holdings.
[AI Summary]Jeil Pharmaceutical's 2025 governance report shows positive steps such as electronic voting, succession planning, and better internal controls. However, two consecutive years without dividends and failure to meet the 4-week AGM notice requirement temper the outlook. While profitability has recovered, restoring dividend capacity and advancing board diversity and chair independence remain key challenges.